Gilvetmab is the first and only immune checkpoint inhibitor developed for the treatment of mast cell tumors (MCTs) and melanomas in dogs.
LEARN MOREA powerful first-line, broad-spectrum topical medication administered twice a day for 7 days to treat otitis external in dogs.
LEARN MOREFirst and only non-adjuvanted feline leukemia virus (FeLV) vaccine built on RNA particle technology
LEARN MOREFirst and only canine flu vaccine built on RNA particle technology
LEARN MORE